PDCD1 and neoplasm: Avelumab is a fully human antibody that shows a double effect—it prevents the connection of PD-L1 on a tumor cell with PD-1 on T lymphocytes and has ADCC activity, which is induced by binding to receptors on the effector cells of the immune system [53, 54].